Medplus Health Q1 FY27 Earnings Call — Analysis (NSE: MEDPLUS)
MedPlus puts Board-approved non-core capex on hold after investor pushback, refocuses on core pharmacy amid margin pressure from lower private label mix and wage hikes.
The take
Q1FY27 Pharmacy Revenue Growth 21.8% ( +21.8% YoY ) . New guidance — Q2FY27 private label revenue mix 0.25% to 0.3% .
Results
Revenue ₹1,879.6 Cr +21.8% YoY (pharmacy); Consol EBITDA margin 3.5%, down due to lower private label share and higher employee costs; net added 146 stores to reach 5,476.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Total Consolidated Revenue | ₹1,879.6 Cr | point_in_time · Q1FY27 | |
| Pharmacy Revenue Growth | 21.8% | +21.8% | yoy · Q1FY27 |
| Consolidated Operating EBITDA | ₹65.1 Cr | none · Q1FY27 · 3.5% margin | |
| Pharmacy Operating EBITDA | ₹58.8 Cr | none · Q1FY27 · 3.2% margin | |
| Diagnostics Revenue | ₹37.08 Cr | +₹6.79 Cr | yoy · Q1FY27 · ₹30.29 Cr in Q1FY26 |
| Diagnostics Operating EBITDA | ₹6.59 Cr | +₹2.46 Cr | yoy · Q1FY27 · ₹4.13 Cr in Q1FY26 |
| Store Count (end of period) | 5,476 | +146 | qoq · Q1FY27 · net addition |
| Private Label Pharma Share of Revenue | 10.7% | -200 bps | yoy · Q1FY27 |
| Private Label Total Share of Revenue | 20% | point_in_time · Q1FY27 · pharma 10.7%, non-pharma 9.3% | |
| Store Level EBITDA Margin (>12 months age) | 10.4% | point_in_time · Q1FY27 | |
| Net Working Capital | 54 days | point_in_time · Q1FY27 | |
| Inventory Days (warehouse) | 33 days | point_in_time · Q1FY27 |
Guidance
FY27 net new store addition target of 800 maintained; private label share recovery of 0.25–0.3% per quarter expected from Q2, with full-year gross margin recovery of 100 bps from mix.
What management committed to
- MedPlus will add 800 net new stores (including franchisee stores) in FY27. — 800, FY27
- Overall private label share to increase by 0.25% to 0.3% per quarter sequentially from Q2FY27 onwards. — 0.25% to 0.3%, Q2FY27
- The 100 basis points gross margin impact from lower private label mix will be recovered during the full year FY27. — 100 basis points, FY27
- Non-pharma private label supply disruption (diaper range) will normalise and show full impact by the end of Q2FY27. — Q2FY27
- Membership fee increase from ₹99 to ₹149 will add ₹10–11 Cr to FY27 top line. — ₹10-11 Cr, FY27
- Core pharmacy business capex will continue and will not stop, irrespective of market feedback. — ongoing
- No significant expansion is planned for the diagnostics segment in the near future.
- Management targets returning to the earlier reported EBITDA margin (~9%) in a sustainable manner. — ~9% EBITDA margin
Key themes
Capex reversal and core business refocus amid margin recovery
Operational commentary
- Board-approved capex proposals (food park, wellness/concierge) put on hold following market and investor feedback; core pharmacy capex continues unaffected.
- Store network expanded to 5,476 stores (+146 net); 222 gross openings, 52 closures, 24 COCO-to-franchisee conversions; FY27 guidance of 800 net new stores maintained.
- Large-format stores being tested (47–48 launched) for better fill rates and assortment, contributing to slight increase in average store size to 539 sq ft.
- Private label share dipped (pharma 10.7% vs ~13.8% YoY) due to conscious pullback to avoid customer friction; recovery plan via influencer marketing and sales training targeting 0.25–0.3% sequential increase from Q2.
- Non-pharma private label supply disruption in diaper range; expected to normalise by end of Q2FY27.
- Membership fee increased from ₹99 to ₹149, adding ~₹10–11 Cr annual top line; active membership at 44–45 lakh, up from ~40 lakh YoY.
- Discount structure tweaked: purchases >₹1,000 now get 19% discount (vs 20%) for non-UPI payment modes effective 7 July.
- Significant minimum wage hikes in Karnataka (+60%) and Telangana (+25%) effective June 1; retention bonus plan for new hires stopped from March 1; incentive optimisation underway.
- Franchisee model experimental: 95% of converted stores taken by existing employees but closures remain elevated (avg age of closed franchisees 0.7 years); adjustments to fee support and breakeven timeline in progress.
- Diagnostics profitable at EBITDA ₹6.59 Cr but scaling slower than expected; no significant expansion planned, focus on maintenance.
- New state entry into Chhattisgarh, Madhya Pradesh, and Kerala; contiguously expanding from existing strongholds.
Analyst Q&A
Q. Rationale behind putting approved capex plans on hold and strategic thinking on food park/wellness foray.
Management explained that backward integration and adjacency in prevention/concierge medicine were considered but reversed after market and investor feedback, emphasising sensitivity to stock market reactions.
Q. Why did EBITDA decline YoY despite absolute private label sales being flat?
The decline is due to mix shift (lower private label share) and increased employee costs, primarily from wage hikes in Karnataka and Telangana, with details on mitigation steps.
Q. How should private label share move in coming quarters?
Expect to arrest the degrowth in Q2 and then build up at 0.3–0.5% per quarter through influencer marketing and improved sales skills, targeting full recovery of the 100 bps gross margin impact over the year.
Q. What is the same-store sales growth (SSSG) this quarter?
Management stated they 'do not really track SSSG per se' because it does not work for pharma retail, but acknowledged a number exists in their presentation without providing it on the call.
Q. What is the update on promoter leverage and any timeline for reduction?
The family office is actively evaluating, but no current plan or timeline; adequate disclosures will be made as and when.
Research and educational content only. Not investment advice.